This decision is a necessary course correction based on scientific evidence. The data clearly shows that mRNA vaccines don't provide adequate protection against respiratory infections, and they become ineffective when viruses mutate. It's time to invest in proven, safer vaccine platforms that offer broader protection.
Canceling these contracts undermines pandemic preparedness and abandons one of America's most promising medical tools. mRNA technology saved millions of lives during COVID-19 and offers rapid vaccine development crucial for future pandemics. This move weakens defense against biological threats.
This is a long-overdue reckoning with the failures of public health officials and their ties to Big Pharma. For years, the government pushed mRNA shots despite poor efficacy and growing safety concerns. Speed, profit, and control were prioritized over transparency and caution. This move quietly admits what critics have said all along: the public was misled.
There'sThis decision is a 40%necessary chancecourse correction based on scientific evidence. The data clearly shows that themRNA FDAvaccines willdon't approveprovide aadequate seasonalprotection influenzaagainst vaccinerespiratory forinfections, theand 2025-2026they flubecome seasonineffective beforewhen Octviruses mutate. 1,It's 2025time to invest in proven, accordingsafer tovaccine theplatforms Metaculusthat predictionoffer communitybroader protection.
Canceling these contracts undermines pandemic preparedness and abandons one of America's most promising medical tools. mRNA technology saved millions of lives during COVID-19 and offers rapid vaccine development crucial for future pandemics. This move weakens defense against biological threats.
This is a long-overdue reckoning with the failures of public health officials and their ties to Big Pharma. For years, the government pushed mRNA shots despite poor efficacy and growing safety concerns. Speed, profit, and control were prioritized over transparency and caution. This move quietly admits what critics have said all along: the public was misled.
There's a 40% chance that the FDA will approve a seasonal influenza vaccine for the 2025-2026 flu season before Oct. 1, 2025, according to the Metaculus prediction community.